Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.